Health Care • Biotechnology: Pharmaceutical Preparations
$63.31 ▲ +2.03
(+3.31%)
MKT CAP: $8.80B • VOL: 1.43M
52W L $58 52W H $88
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$53
MEDIAN
$71
MEAN
$72
HIGH
$86
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE CYTK TAPE
CYTK // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $76.61 | $72.81 | 2025-02-14 | $57.61 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $79.77 | $74.71 | 2025-02-06 | $59.51 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $72.17 | $69.64 | 2025-01-29 | $60.78 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $64.58 | — | 2025-01-17 | $62.04 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $55.71 | $60.14 | 2025-01-09 | $56.35 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $75.34 | $65.84 | 2024-12-18 | $55.08 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $61.41 | $63.94 | 2024-12-04 | $58.88 | -4.3% | 48% | C |